Skip to content
Screener

West Pharmaceutical Services WST Common Stock Par Value Per Share

Common Stock Par Value Per Share at other companies

AptarGroup logo
AptarGroupATR
$0.010.0%
Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
$0.000.0%
AVT
AvantorAVTR
$0.01
Dow logo
DowDOW
$0.010.0%
DuPont de Nemours, Inc. logo
DuPont de Nemours, Inc.DD
$0.010.0%
Cumberland Pharmaceuticals logo
Cumberland PharmaceuticalsCPIX
$0.00

Other financials

Income statement

See full
Revenue$872.3M+13.8%
Gross profit$329.2M+20.2%
Operating income$179.1M+16.5%
Net income$154.0M+16.8%
EPS (diluted)$2.15+18.1%

Balance sheet

See full
Cash & equivalents$435.8M-14.5%
Total debt$316.5M+2.7%
Total equity$3.0B+2.1%
Total assets$4.1B+3.1%

Cash flow

See full
Operating cash flow$124.0M-30.0%
CapEx$43.2M-42.6%
Free cash flow$80.8M-20.7%

Valuation

See full
Market cap$24.53B+43.8%
Enterprise value$24.41B+44.8%
P/E43.4×+8.4×
P/S7.4×+1.6×

Profitability

See full
Gross margin36.8%+1.5pp
Operating margin20.5%+0.8pp
Net margin17%+0.5pp
FCF margin13.1%+1.5pp

Returns & leverage

See full
Return on equity19.1%+1.4pp
Debt / equity0.1×0.0×
Current ratio2.8×0.0×

Where this comes from

Reported directly by West Pharmaceutical Services in its filing.

Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.

The source filing: West Pharmaceutical Services’s 10-Q, filed July 23, 2026.

Filed
Jul 23, 2026, 4:15 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000105770-26-000099
(in millions, except per share data)June 30,2026December 31,2025
Commitments and contingencies (Note 16)
Equity:
Preferred stock, 3.0 million shares authorized; 0 shares issued and outstanding
Common stock, par value $0.25 per share; 200.0 million shares authorized; shares issued: June 30, 2026 - 75.3 million, December 31, 2025 - 75.3 million; shares outstanding: June 30, 2026 - 70.4 million, December 31, 2025 - 72.0 million18.818.8
Capital in excess of par value
Retained earnings4,624.14,374.9
Accumulated other comprehensive loss(140.4)(105.5)
Treasury stock, at cost (June 30, 2026 - 4.9 million shares, December 31, 2025 - 3.3 million shares)(1,512.3)(1,112.2)

Item 1. FINANCIAL STATEMENTS (UNAUDITED)

FAQ

What is West Pharmaceutical Services's common stock par value per share?
West Pharmaceutical Services (WST) reported common stock par value per share of $0.25 in Q2 2026.
How has West Pharmaceutical Services's common stock par value per share changed year-over-year?
West Pharmaceutical Services's common stock par value per share decreased by 0.0% year-over-year, from $0.25 to $0.25.
What is the long-term trend for West Pharmaceutical Services's common stock par value per share?
Over 5 years (2020 to 2025), West Pharmaceutical Services's common stock par value per share has grown at a 0.0% compound annual growth rate (CAGR), from $0.25 to $0.25.
What does common stock par value per share mean?
The par value of common stock is the arbitrary legal value assigned to each share of common stock at the time of issuance. It is a legacy accounting requirement that has little impact on the actual market value or trading price of the shares.

Ask your AI about West Pharmaceutical Services's common stock par value per share.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude